NCT06659042View on ClinicalTrials.gov

Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

November 20, 2025

Study Completion Date

November 20, 2027

Conditions
Lung Cancer, Non-Small Cell
Interventions
DRUG

Carboplatin

administered via IV infusion

DRUG

Pemetrexed Disodium

administered via IV infusion

DRUG

Tislelizumab

administered via Intravenous (IV) injection

DRUG

Cisplatin

administered via IV infusion

Trial Locations (1)

Unknown

RECRUITING

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Chest Hospital

OTHER